Melanoma genome sequencing reveals frequent PREX2 mutations, Nature, vol.485, pp.502-506, 2012. ,
A landscape of driver mutations in melanoma, Cell, vol.150, pp.251-263, 2012. ,
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas, Nat Genet, vol.47, pp.996-1002, 2015. ,
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat Genet, vol.44, pp.1006-1014, 2012. ,
Genomic Classification of Cutaneous Melanoma, Cell, vol.161, pp.1681-1696, 2015. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
A genome-based strategy uncovers frequent BRAF mutations in melanoma, Cancer Cell, vol.2, pp.5-7, 2002. ,
A novel AKT3 mutation in melanoma tumours and cell lines, Br J Cancer, vol.99, pp.1265-1268, 2008. ,
PTEN signaling pathways in melanoma, Oncogene, vol.22, pp.3113-3122, 2003. ,
The WNT/Beta-catenin pathway in melanoma, Frontiers in bioscience : a journal and virtual library, vol.11, pp.733-742, 2006. ,
Stabilization of beta-catenin by genetic defects in melanoma cell lines, Science, vol.275, pp.1790-1792, 1997. ,
RAC1P29S is a spontaneously activating cancer-associated GTPase, Proc Natl Acad Sci U S A, vol.110, pp.912-917, 2013. ,
Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism, J Invest Dermatol, vol.132, pp.2610-2621, 2012. ,
Rac1 in the driver's seat for melanoma, Pigment Cell Melanoma Res, vol.25, pp.762-764, 2012. ,
Phosphatidylinositol 3'-kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor-1(alpha) and vascular endothelial growth factor expression, American journal of physiology Heart and circulatory physiology, vol.300, pp.2169-2176, 2011. ,
Recurrent inactivating RASA2 mutations in melanoma, Nat Genet, vol.47, pp.1408-1410, 2015. ,
, Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell, vol.161, pp.1681-1696, 2015.
Focus on cutaneous and uveal melanoma specificities, Genes Dev, vol.31, pp.724-743, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02529958
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma, Cell reports, vol.4, pp.1090-1099, 2013. ,
High frequency of BRAF mutations in nevi, Nat Genet, vol.33, pp.19-20, 2003. ,
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations, J Invest Dermatol, vol.127, pp.179-182, 2007. ,
Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features, Am J Pathol, vol.157, pp.967-972, 2000. ,
The essence of senescence, Genes Dev, vol.24, pp.2463-2479, 2010. ,
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?, Br J Cancer, vol.95, pp.496-505, 2006. ,
Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression, Pigment Cell Melanoma Res, vol.26, pp.226-235, 2013. ,
Human nevi lack distinguishing senescence traits, Aging, vol.5, pp.98-99, 2013. ,
Monitoring oncogenic B-RAF-induced senescence in melanocytes, Methods Mol Biol, vol.965, pp.313-326, 2013. ,
BRAFE600-associated senescence-like cell cycle arrest of human naevi, Nature, vol.436, pp.720-724, 2005. ,
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells, Oncogene, vol.27, pp.6623-6634, 2008. ,
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway, Nat Cell Biol, vol.8, pp.1053-1063, 2006. ,
NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model, Pigment Cell Melanoma Res, vol.28, pp.407-416, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530560
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence, Aging, vol.1, pp.542-556, 2009. ,
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis, Genes Dev, vol.26, pp.1055-1069, 2012. ,
CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma, Cancer discovery, vol.5, pp.1072-1085, 2015. ,
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7, Cell, vol.132, pp.363-374, 2008. ,
IGFBP7 is not required for B-RAF-induced melanocyte senescence, Cell, vol.141, pp.717-727, 2010. ,
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network, Cell, vol.133, pp.1019-1031, 2008. ,
Senescence-messaging secretome: SMS-ing cellular stress, Nat Rev Cancer, vol.9, pp.81-94, 2009. ,
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice, Oncogene, vol.28, pp.2289-2298, 2009. ,
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma, Curr Biol, vol.15, pp.249-254, 2005. ,
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet, vol.41, pp.544-552, 2009. ,
Oncogenic Braf induces melanocyte senescence and melanoma in mice, Cancer Cell, vol.15, pp.294-303, 2009. ,
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background, Cancer Res, vol.65, pp.4005-4011, 2005. ,
DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency', Cell Cycle, vol.6, pp.2344-2347, 2007. ,
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication, Nature, vol.444, pp.638-642, 2006. ,
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence, Genes Dev, vol.21, pp.43-48, 2007. ,
A two-step model for senescence triggered by a single critically short telomere, Nat Cell Biol, vol.11, pp.988-993, 2009. ,
Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer epidemiology, biomarkers & prevention : a publication of the, American Society of Preventive Oncology, vol.16, pp.1499-1502, 2007. ,
Oncogeneinduced telomere dysfunction enforces cellular senescence in human cancer precursor lesions, EMBO J, vol.31, pp.2839-2851, 2012. ,
The longer your telomeres, the larger your nevus?, Am J Dermatopathol, vol.25, pp.83-84, 2003. ,
Genetics of melanoma progression: the rise and fall of cell senescence, Pigment Cell Melanoma Res, vol.29, pp.122-140, 2016. ,
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annual review of pathology, vol.9, pp.239-271, 2014. ,
The signals and pathways activating cellular senescence, The international journal of biochemistry & cell biology, vol.37, pp.961-976, 2005. ,
Telomere maintenance and cancer --look, no telomerase, Nat Rev Cancer, vol.2, pp.879-884, 2002. ,
A caveolindependent and PI3K/AKT-independent role of PTEN in beta-catenin transcriptional activity, Nature communications, vol.6, p.8093, 2015. ,
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development, Genes Dev, vol.21, pp.2923-2935, 2007. ,
Rizos H. p16INK4a-induced senescence is disabled by melanoma-associated mutations, Aging Cell, vol.7, pp.733-745, 2008. ,
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53, Nature, vol.511, pp.478-482, 2014. ,
A genomic screen identifies TYRO3 as a MITF regulator in melanoma, Proc Natl Acad Sci U S A, vol.106, pp.17025-17030, 2009. ,
PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells, Oncogene, vol.31, pp.1484-1492, 2012. ,
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations, Am J Hum Genet, vol.69, pp.765-773, 2001. ,
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study, J Natl Cancer Inst, vol.102, pp.1568-1583, 2010. ,
Genetics of familial melanoma: 20 years after CDKN2A, Pigment Cell Melanoma Res, vol.28, pp.148-160, 2015. ,
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds, Nat Genet, vol.10, pp.351-353, 1995. ,
A melanoma-associated germline mutation in exon 1beta inactivates p14ARF, Oncogene, vol.20, pp.5543-5547, 2001. ,
Targeting CDK4 and CDK6: From Discovery to Therapy, Cancer discovery, vol.6, pp.353-367, 2016. ,
Genetic Modifiers of the p53 Pathway. Cold Spring Harbor perspectives in medicine, vol.6, p.26302, 2016. ,
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma, Nat Genet, vol.12, pp.97-99, 1996. ,
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression, J Natl Cancer Inst, vol.95, pp.723-732, 2003. ,
p16(Ink4a) in melanocyte senescence and differentiation, J Natl Cancer Inst, vol.94, pp.446-454, 2002. ,
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence, Proc Natl Acad Sci U S A, vol.104, pp.10968-10973, 2007. ,
The RB and p53 pathways in cancer, Cancer Cell, vol.2, pp.103-112, 2002. ,
p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes, Pigment Cell Melanoma Res, vol.26, pp.236-246, 2013. ,
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation, Pigment Cell Melanoma Res, 2010. ,
A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility, Nature communications, vol.5, p.5348, 2014. ,
Germline mutation of ARF in a melanoma kindred, Hum Mol Genet, vol.11, pp.1273-1279, 2002. ,
Oxidative stress in melanocyte senescence and melanoma transformation, European journal of cell biology, vol.93, pp.36-41, 2014. ,
Feedback between p21 and reactive oxygen production is necessary for cell senescence, Mol Syst Biol, vol.6, p.347, 2010. ,
BAP1 and cancer, Nat Rev Cancer, vol.13, pp.153-159, 2013. ,
Telomereregulating genes and the telomere interactome in familial cancers, Molecular cancer research : MCR, vol.13, pp.211-222, 2015. ,
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, vol.480, pp.94-98, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00719536
Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history, Pigment Cell Melanoma Res, vol.26, pp.259-262, 2013. ,
Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients, J Invest Dermatol, vol.134, pp.141-149, 2014. ,
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma, Nature, vol.480, pp.99-103, 2011. ,
Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes, J Cell Biol, vol.142, pp.827-835, 1998. ,
URL : https://hal.archives-ouvertes.fr/inserm-02532974
Variants of the melanocytestimulating hormone receptor gene are associated with red hair and fair skin in humans, Nat Genet, vol.11, pp.328-330, 1995. ,
Defining the Contribution of MC1R Physiological Ligands to ATR Phosphorylation at Ser435, a Predictor of DNA Repair in Melanocytes, J Invest Dermatol, vol.135, pp.3086-3095, 2015. ,
Significance of the melanocortin 1 receptor in the DNA damage response of human melanocytes to ultraviolet radiation, Pigment Cell Melanoma Res, vol.27, pp.601-610, 2014. ,
MC1R is a potent regulator of PTEN after UV exposure in melanocytes, Mol Cell, vol.51, pp.409-422, 2013. ,
Melanocytes and the microphthalmia transcription factor network, Annu Rev Genet, vol.38, pp.365-411, 2004. ,
Different cisacting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia, Mol Cell Biol, vol.18, pp.694-702, 1998. ,
Fifteen-year quest for microphthalmia-associated transcription factor target genes, Pigment Cell Melanoma Res, vol.23, pp.27-40, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530740
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature, vol.436, pp.117-122, 2005. ,
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, Nature, vol.504, pp.138-142, 2013. ,
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer discovery, 2014. ,
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nature communications, vol.5, p.5712, 2014. ,
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma, Cancer discovery, 2013. ,
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, 2017. ,
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with proinflammatory cytokine responsiveness and myeloid cell recruitment, Nature communications, vol.6, p.8755, 2015. ,
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness, Genes Dev, vol.20, pp.3426-3439, 2006. ,
Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations, JAMA dermatology, vol.152, pp.405-412, 2016. ,
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression, J Natl Cancer Inst, vol.109, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02529960
Sumoylation of MITF and its related family members TFE3 and TFEB, J Biol Chem, vol.280, pp.146-155, 2005. ,
Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner, Pigment Cell Res, vol.18, pp.265-277, 2005. ,
Mechanisms, regulation and consequences of protein SUMOylation, Biochem J, vol.428, pp.133-145, 2010. ,
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition, Nat Rev Mol Cell Biol, vol.11, pp.861-871, 2010. ,
Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3, Mol Cell Biol, vol.23, pp.9073-9080, 2003. ,
Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes, Mol Cell Biol, vol.24, pp.10584-10592, 2004. ,
Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies, J Cell Biol, vol.182, pp.35-39, 2008. ,
Genetically engineered mouse models in cancer research, Advances in cancer research, vol.106, pp.113-164, 2010. ,
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J Invest Dermatol, vol.122, pp.337-341, 2004. ,
Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma, Cancer discovery, vol.5, pp.723-729, 2015. ,
A germline oncogenic MITF mutation and tumor susceptibility, European journal of cell biology, 2013. ,
Betacatenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor, J Cell Biol, vol.158, pp.1079-1087, 2002. ,
beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas, Cancer Cell, vol.20, pp.741-754, 2011. ,
SUMOylation and cell signalling, Biotechnology journal, vol.4, pp.1740-1752, 2009. ,
Roles for SUMO modification during senescence, Adv Exp Med Biol, vol.694, pp.160-171, 2010. ,
SUMO and the robustness of cancer, Nat Rev Cancer, vol.17, pp.184-197, 2017. ,
Ultraviolet radiation and cutaneous malignant melanoma, Oncogene, vol.22, pp.3099-3112, 2003. ,
Skin hypoxia: a promoting environmental factor in melanomagenesis, Cell Cycle, vol.5, pp.1258-1261, 2006. ,
The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs, Cell reports, vol.7, pp.1815-1823, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02191559
The Role of Sumoylation in Senescence, Adv Exp Med Biol, vol.963, pp.215-226, 2017. ,
Positive and negative elements regulate a melanocyte-specific promoter, Mol Cell Biol, vol.12, pp.3653-3662, 1992. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N Engl J Med, vol.372, pp.2521-2532, 2015. ,
Challenging resistance mechanisms to therapies for metastatic melanoma, Trends Pharmacol Sci, vol.34, pp.656-666, 2013. ,
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis, Science, vol.335, pp.348-353, 2012. ,
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9, Proc Natl Acad Sci U S A, vol.112, pp.1724-1733, 2015. ,
Advances in the development of SUMO specific protease (SENP) inhibitors, Computational and structural biotechnology journal, vol.13, pp.204-211, 2015. ,
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer, EBioMedicine, vol.8, pp.30-39, 2016. ,
Microphthalmiaassociated transcription factor controls the DNA damage response and a lineagespecific senescence program in melanomas, Cancer Res, vol.70, pp.3813-3822, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530789
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome ,
URL : https://hal.archives-ouvertes.fr/inserm-02530715
, Genes Dev, vol.25, pp.1245-1261, 2011.
Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma, Oncogene, vol.30, pp.2319-2332, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530755
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy, Cell, vol.109, pp.335-346, 2002. ,
DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res, vol.62, pp.1876-1883, 2002. ,
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kappaB impairs this drug-induced senescence, EMBO molecular medicine, vol.5, pp.149-166, 2013. ,
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, vol.445, pp.656-660, 2007. ,
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy, Nature, 2013. ,
Reversal of human cellular senescence: roles of the p53 and p16 pathways, Embo J, vol.22, pp.4212-4222, 2003. ,
The senescence-associated secretory phenotype: the dark side of tumor suppression, Annual review of pathology, vol.5, pp.99-118, 2010. ,
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion, Nat Cell Biol, vol.11, pp.973-979, 2009. ,
Chemokine signaling via the CXCR2 receptor reinforces senescence, Cell, vol.133, pp.1006-1018, 2008. ,
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype, Oncotarget, vol.4, pp.2212-2224, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530603
Carcinomaassociated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res, vol.59, pp.5002-5011, 1999. ,
Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype, J Biol Chem, vol.286, pp.36396-36403, 2011. ,
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice, Nat Med, vol.22, pp.78-83, 2016. ,
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature, vol.479, pp.232-236, 2011. ,
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging, Cell, vol.169, pp.132-147, 2017. ,
Clinical strategies and animal models for developing senolytic agents, Experimental gerontology, vol.68, pp.19-25, 2015. ,
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs, Aging Cell, vol.14, pp.644-658, 2015. ,
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors, Aging Cell, vol.15, pp.428-435, 2016. ,
Vemurafenib induces senescence features in melanoma cells, J Invest Dermatol, vol.133, pp.1601-1609, 2013. ,